From October 1, 2025, the US will impose 100% tariffs on branded drugs. India’s pharma exports face a major blow, exposing the Modi government’s failure to shield vital industries.

Beginning October 1, 2025, the US will levy a 100% tariff on branded and patented medicines unless companies set up plants in America. President Trump claimed this move would safeguard US manufacturers, but it spells trouble for India’s pharmaceutical sector, which heavily depends on exports to the American market.

The US already accounts for nearly one-third of India’s pharma exports, and firms like Dr. Reddy’s, Sun Pharma, and Aurobindo Pharma rely on it for a significant share of their revenue. With additional 50% duties on Indian imports and penalties linked to Russian oil trade, the squeeze on India’s economy is becoming tighter.

While Washington justifies tariffs as “national security” measures, New Delhi’s silence shows how unprepared the government is to protect critical industries. Endless celebrations of “global leadership” mean little when Indian workers, exporters, and small suppliers will pay the price.

Analysis For India, this isn’t just a trade challenge — it’s a test of political will. Instead of hollow slogans, the government must aggressively negotiate exemptions, diversify markets, and support pharma companies facing losses. Without immediate intervention, millions of jobs linked to India’s pharma supply chain could be at risk, while US patients may face higher drug costs.